GLP-1 In Dubai: The Complete Guide To Metabolic Medicine (2025)

In recent years, GLP-1 receptor agonists, which, if you’ve never heard of them before, are the class of medications that includes Ozempic, Wegovy, Mounjaro, and Saxenda, among others, have produced some of the most significant shifts in metabolic medicine in a generation. That’s not just a bold marketing claim, either, as there is now a sizeable catalogue of scientifically proven studies to back this up, and the clinical trial results are genuinely remarkable.

‍

For example, we have patients on semaglutide who are losing 15% of their body weight over 68 weeks, not to mention tirzepatide, producing more than 20%+ weight reduction in a significant proportion of trial participants. Then, we have cardiovascular outcomes data, which shows meaningful reductions in heart attack and the risk of a stroke that go well beyond what weight loss alone would predict.

Why Has GLP-1 Become So Popular In Dubai?

‍

Dubai, given its unique environment, sociological topography, and typical patient profile, has taken notice. Over the past 2 years alone, demand for GLP-1 prescriptions in the UAE has skyrocketed dramatically, which has introduced knock-on effects that have seen the rise of online platforms offering video consultations and even home delivery. Moreover, there are aesthetic clinics with no metabolic medicine expertise beforehand, who can now be found prescribing injectable weight loss medications, too.

‍

Nevertheless, despite all the buzz and excitement around GLP-1 recently, almost every single conversation in this market goes silent, and has collapsed almost entirely around one pertinent question: which GLP-1 injection should I get? Granted, that’s maybe the wrong question to ask.

‍

We know that GLP-1 therapy works. However, it works best and most safely when it has become the centrepiece of a comprehensive metabolic protocol, rather than being used as a standalone injection. To understand why, we first need to understand what these medications do, what they do not do, and what happens to your body when the medication alone is used without all the clinical infrastructure that makes the results sustainable. In this detailed guide on GLP-1 therapy, we’ll bare it all.

What Is GLP-1?

‍

GLP-1, which is also known as “glucagon-like peptide-1”, is a type of hormone that is produced naturally in the intestine in response to food intake. Rather than just one or two unique roles that it plays within your complex physiological profile, it actually has several more distinct functions which, altogether, would make GLP-1 one of the most metabolically significant hormones in your body. Here are some of the important roles:

1. Insulin Secretion

‍

GLP-1 works by stimulating the pancreas to release insulin in response to an elevated blood glucose level. Critically, this stimulation is highly glucose-dependent, and GLP-1 would only trigger an insulin release when your blood sugar level is elevated.

‍

As a result, this is why GLP-1 receptor agonists have a comparatively low risk of causing hypoglycaemia in non-diabetic patients.

2. Glucagon Suppression

‍

In addition, GLP-1 suppresses the release of glucagon, which is the hormone that tells your liver to release stored glucose.

‍

While it might not sound like much, by reducing glucagon, GLP-1 could keep your blood sugar levels from rising unnecessarily between meals.

3. Gastric Emptying

‍

Other than insulin and glucagon, and speaking of meals, GLP-1 slows the rate at which food leaves your stomach.

‍

Consequently, this would produce a more gradual postprandial blood glucose rise in your body, thus creating a more sustained sensation of fullness, which ought to reduce unnecessary caloric intake.

4. Central Appetite Regulation

‍

GLP-1 receptors can be found active in the hypothalamus and brainstem, which are the critical regions of your brain that are responsible for regulating hunger, satiety, and food reward. Therefore, GLP-1 receptor activation in the brain reduces your appetite, while also increasing fullness signalling (i.e., that sense of a full belly after eating).

‍

Additionally, and this is also what many patients describe as the most significant effect of GLP-1 activation, it quiets the constant background noise of food thoughts (i.e., constantly thinking about, imagining, and being hungry for food) that characterises the core problem of chronic overconsumption.

5. Cardiovascular Protection

‍

Last but not least, you’ll find GLP-1 receptors that are expressed in the heart and your vasculature. GLP-1 receptor agonists have demonstrated direct cardioprotective effects in the past, which include reducing inflammation and improving endothelial function.

‍

Aside from that, clinical studies have further found that GLP-1 is quite effective when it comes to producing significant reductions in major cardiovascular events in multiple landmark trials. Most interestingly, these appear to operate independently of its weight loss characteristics.

‍

In summary, GLP-1 receptor agonists are synthetic molecules designed to activate your GLP-1 receptors much more potently and keep them active for longer than endogenous GLP-1, which can be degraded within minutes by the enzyme DPP-4. The injectable formulations often relied upon in clinical use, by comparison, have half-lives of days to weeks, and they’re able to consistently produce a sustained receptor activation from just a single weekly injection.

The GLP-1 Medications Available In Dubai

‍

Having now understood what GLP-1 is and how it all works, it’s equally important to understand the landscape of available GLP-1 medications. This is essential before any clinical decision can be made, because they are not so easily interchangeable. With that in mind, here’s a rundown of the most common GLP-1 medications that you would find currently available in Dubai:

Semaglutide (Ozempic / Wegovy)

‍

Semaglutide is a very particular GLP-1 receptor agonist that was first developed by the pharmaceutical giant, Novo Nordisk. Currently, it’s available in either one of two branded formulations, though each of them carries different approved indications:

‍

• Ozempic - This is approved for Type 2 diabetes management, and it’s readily available in doses up to 2 mg weekly. In clinical practice and within a clinical setting, Ozempic is very frequently prescribed off-label for better weight management in non-diabetic patients with obesity or metabolic dysfunction, which is a use that has been supported widely by robust evidence, even though its sister formulation, Wegovy, carries the formal weight management indication.

‍

• Wegovy - It’s the higher-dose semaglutide formulation between the two, up to 2.4 mg weekly, which has been approved specifically for chronic weight management in adults with obesity or if they’re overweight with at least one weight-related comorbidity. The STEP (Semaglutide Treatment Effect in People with obesity) trial programme has since demonstrated an impressive average weight loss of approximately 15% at 68 weeks.

‍

• Oral Semaglutide (Rybelsus) - This is available as a daily tablet at doses up to 14 mg, though its bioavailability is significantly lower than injectable semaglutide. In addition, its clinical weight loss outcomes are correspondingly more modest compared to either the use of Ozempic or Wegovy. Nonetheless, Rybelsus remains a rather useful option and alternative for patients with a strong aversion to needles and injections, or for patients who simply cannot use injectable formulations.

Tirzepatide (Mounjaro / Zepbound)

‍

Tirzepatide is a dual GIP/GLP-1 receptor agonist that was first developed by one other pharmaceutical giant, Eli Lilly. In principle, it works by activating both your body’s GLP-1 receptor and your GIP receptor. The latter is actually a glucose-dependent insulinotropic polypeptide, which is a second incretin hormone that enhances insulin secretion, and it has direct effects on adipose tissue metabolism.

‍

This very unique dual mechanism produces meaningfully superior weight loss outcomes when compared to just GLP-1 agonists alone. In clinical studies, the SURMOUNT-1 trial demonstrated an average weight loss of 20.9% at the highest dose, which is 15 mg per week, with approximately 57% of all participants achieving a ≥20% weight reduction. These impressive outcomes were previously only achievable with bariatric surgery.

‍

There are two common tirzepatide-based medications. The first is Mounjaro, which is designed to carry the Type 2 diabetes indication in most markets, including here, in the UAE. Meanwhile, there’s also Zepbound, which carries the obesity indication, and it has even been approved for use in the United States back in late 2023. Within a Dubai-based clinical setting, Mounjaro is the most commonly available tirzepatide formulation.

‍

In all, though, tirzepatide is currently the most clinically effective pharmaceutical option for weight loss management. In our case, for patients without any contraindications and for those with fairly significant weight loss goals, it’s actually the first-line option here at Chairon House.

Liraglutide (Saxenda / Victoza)

‍

Other than the previous two, there is also a third, lesser-known option: liraglutide. This is an older GLP-1 receptor agonist that requires a daily injection, unlike the much more convenient and manageable weekly semaglutide and tirzepatide formulations.

‍

Being a slightly older formulation, now usually surpassed by the latter two (semaglutide and tirzepatide), the weight loss outcomes that you can expect are normally much more modest than the newer agents, typically 5% to 8% at the 3 mg dose.

‍

Nevertheless, while it might no longer be as potent or as efficient as those two newer formulations, liraglutide remains a valid option and alternative for patients with specific clinical profiles or tolerability considerations. Still, for new patients who are initiating a GLP-1 therapy protocol, it has largely been superseded by semaglutide and tirzepatide.

The Evidence: What The Clinical Trials Show

‍

The current set of clinical trial data for GLP-1 receptor agonists is among the strongest that we have right now in modern metabolic medicine. Here’s a detailed summary, as well as a timeline of the landmark trials:

‍

• STEP 1 (Wegovy / semaglutide, NEJM 2021) - 1,961 adults with obesity or overweight were assessed, and overall, the trial had documented an average weight loss of 14.9%, higher than the 2.4% placebo, over a period of 68 weeks. In total, 86.4% of participants had lost more than 5% of body weight during the trial period.

‍

• SURMOUNT-1 (Mounjaro / tirzepatide, NEJM 2022) - 2,539 adults with obesity were assessed, and at the conclusion of the trial, there was an average weight loss of 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, over a lengthy trial period of 72 weeks. This represented a notable step-change in pharmaceutical weight management efficacy.

‍

• SELECT (semaglutide cardiovascular outcomes, NEJM 2023) - 17,604 adults with a selection of either overweight and/or obesity, as well as participants with an established cardiovascular disease, but no diabetes. Semaglutide was able to reduce the risk of any major adverse cardiovascular events by 20% compared to the placebo. Ultimately, this was a strong result that formally established GLP-1 therapy as a clinically proven form of cardiovascular medicine, not merely metabolic medicine.

‍

• SURMOUNT-MMO (tirzepatide cardiovascular outcomes, ongoing) - The results of this clinical trial remain ongoing for now, though they are anticipated to demonstrate whether there is any cardiovascular advantage that is comparable to, or exceeding, the SELECT trial findings for tirzepatide.

‍

Although it’s easy to be sceptical of new, emerging medicines and forms of treatment, the clinical evidence for the efficacy of GLP-1-based medications is robust. However, what the trial data does not adequately capture, and what the Dubai market here has largely failed to grapple with, is the question of body composition and what GLP-1 does for it.

The Problem That Nobody Is Talking About: Muscle Loss

‍

This here is probably the most important and pertinent section of our in-depth guide on GLP-1, especially for patients who are considering GLP-1 therapy in Dubai. Moreover, it’s currently the most consistently underemphasised and often not-talked-about aspect of GLP-1 prescriptions in this market.

‍

GLP-1 medications, as we’ve learned thus far, produce weight loss outcomes through caloric restriction. In other words, the GLP-1 medications reduce your appetite and food intake, as your body creates a caloric deficit, and subsequently, weight is lost. 

‍

The issue here is that under strict conditions of caloric restriction, without adequate protein intake and resistance training practice, a significant proportion of the weight lost actually comes from lean muscle mass instead of fat.

‍

Estimates that we have from established clinical practice and emerging trial data would suggest that, without appropriate nutritional and exercise support, anywhere from 25% to 40% of the weight loss from taking GLP-1 therapy may be lean mass rather than fat. This, of course, can have several serious consequences if left unchecked:

‍

• Metabolic Rate Reduction - Bear in mind that your muscles are the primary site of your resting metabolic rate. As such, losing significant lean mass reduces the basal metabolic expenditure, which often leads to situations where you would require fewer calories at baseline. This is a significant contributor to the weight regain that typically occurs when GLP-1 medications are discontinued.

‍

• Physical Function Decline - When it comes to older patients, in particular, the loss of lean mass during their GLP-1 therapy produces a measurable reduction in grip strength, walking speed, and functional capacity. As you could imagine, these are consequences that far outlast the weight loss benefit and represent a genuine health risk to patients.

‍

• Body Composition Without Aesthetic Improvement - Some patients could lose up to 15% of body weight on GLP-1 therapy, and as a result, they might find that their body composition, which is the ratio of fat to lean mass, has not improved proportionally. The actual scale reflects the medication’s true effect, while the mirror and the DEXA scan tell a different story altogether.

‍

• Bone Density - Emerging clinical research data suggest that GLP-1 therapy may reduce the density of bone mineral in your body, which can be a very significant risk to take into account, compounded even further by lean mass loss.

‍

The clinical solution to all of these problems is actually quite straightforward, but it does require, on your part, very active management to ensure that you can get a meaningful outcome. This would include:

‍

• Adequate protein intake (a minimum of 1.2 g to 1.6 g per kilogram of body weight daily, potentially higher if need be).
• Progressive resistance training is done throughout the entire treatment period.
• Body composition monitoring using a DEXA scan rather than scale weight alone.

‍

This is precisely why the “prescribe-and-monitor” model that characterises most GLP-1 provisions that you see here in Dubai, which include medication, monthly check-ins, and repeat prescriptions, is clinically insufficient, especially for a significant proportion of the typical patient profile that we regularly see. Remember, the actual medication itself is only a small part of the complete protocol.

What Does A Proper GLP-1 Protocol Look Like?

‍

Here, at Chairon House, the typical GLP-1 therapy is integrated into a comprehensive metabolic medicine programme, not just prescribed on its own. Moreover, we often say to our patients that these additional components are not optional extras, but they’re the clinical infrastructure that determines whether or not the outcomes from your specific GLP-1 therapy are genuinely transformative, or if they’re merely temporary.

‍

If you are curious about considering a GLP-1 therapy protocol with us here at Chairon House, here’s an outline of what a thorough, complete GLP-1 protocol looks like:

Phase 1: Pre-Treatment Assessment

‍

Now, for us to attain a complete patient profile for you, and thus, be able to personalise a GLP-1 protocol tailored to your current physiological condition and health goals, a full metabolic workup is completed, and this is done before a prescription is even written:

‍

• HbA1c, fasting glucose, and fasting insulin (this is done to establish a baseline metabolic status and rule out any potential contraindications)

‍

• Full lipid panel and some liver function tests

‍

• Thyroid panel (hypothyroidism is both a common cause of treatment-resistant weight gain, and it’s a vital consideration when looking at contraindications)

‍

• Renal function (GLP-1 agents can affect your gastric motility and fluid balance)

‍

• Personal and family history of medullary thyroid carcinoma or MEN2 (these are absolute contraindications to GLP-1 therapy)

‍

• History of pancreatitis (this is a relative contraindication, but it requires a very careful assessment, nevertheless)

‍

• DEXA scan for your composition baseline, which is essential for tracking the changes in fat mass versus lean mass throughout the treatment period

‍

• Continuous glucose monitoring (CGM), where you might suspect some insulin resistance, is one of the most informative tools for understanding a patient’s metabolic phenotype before designing their individualised GLP-1 protocol.

Phase 2: Medication Selection And Dose Titration

‍

Selecting the right medication for you will be based on your full clinical picture, including mission-critical factors that we have to account for, including your weight loss goals, metabolic status, cardiovascular risks, tolerability profile, and the costs.

‍

Tirzepatide (Mounjaro) is typically our first-line recommendation for patients who have significant weight loss goals and no contraindications. Meanwhile, semaglutide is often preferred in specific clinical contexts. In short, there’s no one-size-fits-all answer.

‍

Furthermore, the dose titration is done gradually, and it’s individualised for each patient. The actual pace of dose titration is important because we’ve found that too-rapid dose escalation can lead to side effects like nausea, vomiting, and gastrointestinal problems, which can easily cause a significant proportion of patients to discontinue GLP-1 therapy altogether, blaming the side effects instead.

‍

With that in mind, a more conservative, patient-specific titration schedule, and one that prioritises tolerance over speed, can help to substantially reduce the risk of causing any unwanted side effects. Besides, there are no clinical benefits to reaching the maximum dose faster than the patient’s gastrointestinal system can realistically accommodate.

Phase 3: The Movement And Recovery Protocol

‍

This phase is where Chairon House’s integrated facility design becomes a clinical asset rather than just a lifestyle amenity. Whereas most GLP-1 providers in Dubai prescribe a medication and then send patients to find their gym, at Chairon House, the movement and recovery infrastructure takes place under the same roof as the clinical team. This is a big deal, as it has changed what is clinically possible.

A) Lagree Megaformer Training

‍

This has become the primary resistance modality for many GLP-1 patients, where you get slow, controlled, high-tension work across your entire body. In doing so, it can easily target every major muscle group in your body through eccentric and isometric loading.

‍

It is among the most effective resistance training methods if you want to simultaneously build lean mass while also improving cardiovascular fitness. For GLP-1 patients, in particular, Lagree creates the anabolic stimulus that tells your body to preserve any lean tissue during caloric restriction.

‍

Sessions with us here at Chairon House are normally integrated into a protocol that has been designed around each patient’s current metabolic status, starting dose, and their body composition baseline. Furthermore, the training frequency and load progression are adjusted as the GLP-1 dose escalates, and your specific body composition data will be reviewed in detail.

B) Hybrid Fitness Conditioning

‍

This particular conditioning programme combines HYROX-style functional training with aerobic capacity and loaded movement, which is incorporated specifically for patients who have a higher existing fitness baseline than others, and/or those with more specific performance goals alongside body recomposition.

‍

For the Dubai performance community, who are already training in this modality, GLP-1 therapy and hybrid conditioning can still work well together. You have the medication itself, which reduces the caloric excess that’s driving fat accumulation, and then you get the conditioning programme, which preserves and builds the cardiovascular and functional capacity that matters to this specific patient group.

‍

Together, the sort of hybrid conditioning programming that we often recommend to our patients here at Chairon House is calibrated to avoid the high-cortisol, catabolic training states that would otherwise accelerate lean mass loss during caloric restriction.

C) Infrared Sauna

‍

Compared to the prior, more active and physically-demanding elements, the infrared sauna is made to be a therapeutically meaningful component of our GLP-1 movement and recovery protocol, though to be clear, it’s not just a passive amenity. 

‍

Far-infrared exposure is proven to improve peripheral insulin sensitivity, which is the mechanism that involves GLUT4 transporter activation in muscle and adipose tissue, which operates independently of GLP-1’s own insulin-sensitising effects.

‍

Aside from that, the infrared sauna is known to be clinically addictive, but best of all, it’ll help to support your cardiovascular adaptation and reduce systemic inflammation (which is highly relevant, given GLP-1’s own anti-inflammatory effects).

‍

Plus, perhaps most critically for patients in the GI (gastrointestinal) adaptation phase of dose escalation, it’s able to promote a parasympathetic recovery that reduces nausea and abdominal discomfort. The typical session takes between 20 and 30 minutes, and it’s done 3 to 4 times each week, which is also integrated right into the protocol.

D) Cold Plunge

‍

Following the infrared sauna in the contrast therapy sequence, you’re then encouraged to take a cold plunge. This contrast in temperature between the hot sauna and the cold pool is intentional, as cold exposure activates brown adipose tissue thermogenesis.

‍

This is the metabolically active fat that generates heat by burning calories, and as such, it’s then able to produce a catecholamine response that further supports fat oxidation, in addition to reducing appetite-driven cravings, independent of the GLP-1 mechanism.

‍

Aside from what’s going on with your metabolism, the physiological component matters when you’re doing a cold plunge, too. A cold plunge practice builds stress tolerance and attentional control that reinforces all of the behavioural changes that your GLP-1 protocol is designed to establish permanently, anyway.

E) Recovery Massage

‍

Last but not least, we have also integrated a recovery massage, spread throughout the entire programme, and set at medically relevant points in the protocol. Granted, this is primarily done during the dose escalation phases, right when most of our patients might be experiencing a lot of fatigue and reduced training tolerance, and at defined body composition checkpoints.

‍

There are physiological reasons behind the massages, as well. A sports massage and lymphatic draining both serve the GLP-1 patient in very specific ways: firstly, a reduced caloric intake limits your body’s natural recovery capacity, and secondly, soft tissue work would support the muscular recovery that resistance training demands.

‍

It’s not recommended to skip this part, as patients who have skipped the vital recovery phase are more likely to be forced to reduce their training frequency during challenging protocol weeks, which is precisely when maintaining your anabolic stimulus matters the most.

F) Summary

‍

Altogether, when combined, these components of our movement and recovery GLP-1 protocol do not make it a wellness menu. They are, in fact, a scientifically grounded and clinically proven, structured recovery architecture that has been designed around the specific physiological demands of a person’s body when they’re undergoing significant metabolic changes that often happen under GLP-1 therapy.

‍

Training frequency, an infrared sauna, and the cold plunge, with the right scheduling and timed well with a recovery massage, are all coordinated with our clinical team here at Chairon House, and it’s not left to patient preference. We do this to ensure that you’d be able to enjoy the best possible outcome from your GLP-1 therapy protocol. This isn’t an optional add-on, either, but it’s what makes the clinical results sustainable.

Phase 4: Nutritional Architecture

‍

And, of course, your nutrition plays an important role during your GLP-1 therapy. On the bright side, it’s not as bad as it sounds, as the nutritional component of a well-designed, comprehensive GLP-1 protocol is not a calorie-restricted diet plan.

‍

Rather, GLP-1 medications already reduce your caloric intake dramatically, and the clinical challenge for us here is to ensure that the reduced caloric intake is nutritionally adequate for you, rather than merely being reduced for the sake of it.

‍

When planning a nutritional architecture for our patients taking our GLP-1 therapy, here is where our key priorities lie:

‍

• Protein Sufficiency - This is, by far, the most important singular dietary variable here. A bare minimum of 1.2 g of protein per kilogram of body weight is a good starting point, or we can even go even higher than this, to 1.6 g or above, for patients who are undergoing resistance training. This step typically requires an active nutritional planning given the appetite suppression that the GLP-1 medication produces, and if we’re not careful, any of our patients can easily under-eat protein when their overall appetite is reduced.

‍

• Micronutrient Density - On that note, a reduced caloric intake often does increase the risk of micronutrient deficiency. Therefore, a diet that prioritises nutrient-dense foods over caloric restriction alone should offer ample protection against the micronutrient depletion that would contribute to fatigue, hair loss, and even an immune dysfunction in poorly managed GLP-1 patients.

‍

• Hydration - It sounds simple, but it’s consequential to a good GLP-1 therapy protocol. It is well-known that GLP-1 medications slow gastric emptying and reduce thirst signals in some patients, thus making it seem as though they don’t need to hydrate as much, even though they should. When combined with Dubai’s tropical heat and unforgiving climate, inadequate hydration is another consistent issue that we usually see here that requires very active monitoring of all GLP-1 patients.

‍

• Alcohol - Additionally, GLP-1 receptor activation in the brain affects reward signalling in ways that extend beyond consuming food. Some of our GLP-1 patients even experience a reduced craving for alcohol, which, in actuality, is a beneficial effect. Granted, we have other patients here who continue drinking at previous, pre-protocol levels despite the reduced caloric intake levels elsewhere, further compounding hepatic and metabolic stress. Either way, both patterns also require close clinical monitoring and awareness.

Phase 5: Adjunctive Clinical Protocols

‍

If you have other health goals and clinical needs that can’t be resolved by GLP-1 alone, then there’s good news, because GLP-1 therapy integrates and pairs very naturally with several other clinical interventions offered here at Chairon House:

A) NAD+ IV Therapy

‍

Metabolic health improvements normally require good cellular energy support for a compounding effect. 

‍

In this context, NAD+ IV (intravenous) therapy supports your mitochondrial efficiency and sirtuin-mediated metabolic regulation. As a result, this creates a more favourable cellular environment for fat oxidation and muscle preservation while you’re undergoing your GLP-1 protocol. 

‍

Patients consistently report that their energy levels and cognitive clarity are better maintained through their GLP-1 dose escalation phases when NAD+ IV therapy is running concurrently.

B) Peptide Protocols

‍

Other than that, specific peptides can also be integrated based on a specific patient’s individual clinical picture. 

‍

For example, for patients prioritising body composition together with weight loss, growth hormone secretagogues, which include Sermorelin or CJC-1295 (Ipamorelin), can work to support lean mass preservation. 

‍

On the other hand, for patients with GI discomfort during the dose escalation procedure, BPC-157 might be considered for its gastrointestinal mucosal support properties, too.

C) GLP-1 Companion Supplementation

‍

This is a very specific supplement stack, which aims to support the physiological demands of GLP-1 therapy, and the typical set often includes (and, for the patient’s convenience, all of these are available as part of Chairon House’s D2C supplement programme, too):

‍

• Electrolytes and magnesium (to counter the increased losses from reduced food intake and increased urinary excretion)

‍

• Digestive enzymes (to support GI function during the adaptation period)

‍

• High-dose vitamin D and K2 (for bone density support)

‍

• Omega-3 fatty acids (for anti-inflammatory and cardiovascular support)

Phase 6: Monitoring And Body Composition Tracking

‍

We’ve found that a monthly scale weight is an inadequate tracking tool when it comes to GLP-1 therapy. At Chairon House, we have other, more accurate means of tracking a patient’s body composition, and you can expect to be monitored with:

‍

• DEXA Scan - This is done at baseline, 12 weeks in, and 24 weeks in post-protocol, and we can even do it sooner, if any body composition concerns arise. This is often the only reliable way to properly distinguish fat loss from lean mass loss.

‍

• Metabolic Markers - HbA1c, fasting insulin, lipid panel, and liver function, all of which are tracked in detail throughout the length of your protocol to confirm that metabolic improvements are occurring, and it’s not just weight reduction.

‍

• CGM Data - For patients who are already using continuous glucose monitoring (CGM), glucose variability and postprandial peaks can be tracked alongside their weight and body composition to build a more detailed, complete patient profile.

‍

• HRV & Training Data - These are objective recovery metrics that inform us about the training load adjustments during the dose escalation phases.

Phase 7: The Exit Strategy

‍

Oftentimes, this is usually the most neglected aspect of GLP-1 prescribing in Dubai, which is unfortunate, because it’s undoubtedly among the most important phases of a person’s weight loss journey.

‍

It’s important to bear in mind that GLP-1 medications are not indefinite treatments for most patients. Instead, they are a metabolic intervention with a defined arc, and as such, there is a starting point and an end point, which should be accompanied by a clear exit strategy on the way out.

‍

The clinical evidence is unambiguous, too, as the majority of patients regain significant weight when GLP-1 medications are discontinued without an adequate exit strategy. To be clear, an exit strategy is not a plan to stop using the medication. 

‍

Rather, it is a detailed plan to make discontinuation possible through the establishment of sustainable metabolic habits, sufficient lean mass to support a higher resting metabolic rate, and a realistic maintenance protocol that the patient can reliably sustain without pharmaceutical appetite suppression.

‍

For most patients, this would mean:

‍

• A minimum of 12 to 18 months on their respective GLP-1 protocols before dose reduction can be safely considered.

‍

• Having to establish resistance training practice and a nutritional approach that does not depend on appetite suppression to be maintained. 

‍

• A graduated dose reduction is preferred, rather than an abrupt stop, whereby the latter often reliably produces rapid weight regain if you’re not careful.

Who Should Consider GLP-1 Therapy In Dubai?

‍

With all that being said, although GLP-1 therapy can bring a lot of meaningful benefits, it is not appropriate for just about everyone who wants to lose weight, and at times, it isn’t even the right starting point for everyone who needs to.

‍

Therefore, a thorough clinical assessment and consultation can help to determine your suitability for GLP-1, but for context, here’s a rundown of the case studies and scenarios that would make you the appropriate candidate for GLP-1 therapy:

‍

• Adults with a BMI of ≥30 (obesity), or a BMI of ≥27 with at least one weight-related comorbidity, such as Type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, or cardiovascular disease.

‍

• Adults with Type 2 diabetes or pre-diabetes and inadequate glycaemic control despite making lifestyle modifications to improve it.

‍

• Adults with an established cardiovascular disease, where the SELECT or SURMOUNT cardiovascular data creates a strong clinical argument for GLP-1 therapy independent of weight.

‍

• Adults who have made sustained, good-faith lifestyle efforts but have not yet produced adequate metabolic improvement.

‍

Nonetheless, this broad profile does not make GLP-1 therapy suitable for everyone, and here are some patient profiles that require very careful clinical assessment before you even consider GLP-1 therapy:

‍

• History of pancreatitis (this is a relative contraindication, and an individual risk-benefit assessment is required beforehand).

‍

• Significant GI disease, such as inflammatory bowel disease and gastroparesis.

‍

• Significant renal impairment.

‍

• Pregnancy or if you are breastfeeding (this is also contraindicated).

‍

• History of eating disorders (GLP-1 medications dramatically alter your relationship with food and hunger, so this requires a detailed psychiatric assessment and ongoing support in especially vulnerable patients).

‍

Otherwise, here are some patient profiles that make them absolute contraindications, so GLP-1 therapy is typically off the table if you can identify with any one of these:

‍

• Personal or family history of medullary thyroid carcinoma.

‍

• Multiple Endocrine Neoplasia type 2 (MEN2).

‍

• Known hypersensitivity to the active substance (GLP-1).

Risks, Side Effects, And How We Manage Them

‍

While it is understandable that some patients might be quite hesitant to try out any new or emerging medicines and forms of treatment, the side effects and safety profile of GLP-1 receptor agonists have since been very well-characterised and made even more manageable with the appropriate clinical support.

‍

For reference, here are some of the more common side effects that you might come across from our past and present patients who have undergone GLP-1 therapy here at Chairon House:

‍

• Gastrointestinal Effects - This is, by far, the most common side effect that patients on a GLP-1 protocol often report, though it is dose and rate-dependent. It would include side effects like nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, all of which are the most frequently reported among patients, especially during the dose escalation phase. However, these side effects can be substantially reduced by adopting a more conservative titration, starting with the lowest dose and escalating slowly, based on a patient’s tolerance instead of protocol speed. Plus, additional dietary modifications, like eating smaller, lower-fat meals, reducing alcohol intake, and maintaining adequate hydration, further reduce your GI burden. In most patients, though, these GI symptoms often resolve themselves within 4 to 8 weeks of reaching a stable dose.

‍

• Fatigue (During Dose Escalation) - Specifically, some patients would experience an increased level of fatigue during the first weeks at each new dose level. This is normally transient and responds naturally to the nutritional and NAD+ support components of your integrated GLP-1 protocol.

‍

• Hair Thinning (Telogen Effluvium) - A smaller proportion of patients, particularly those with rapid early hair loss, have experienced temporary hair thinning 2 to 4 months into treatment. This is usually driven by a caloric restriction rather than the GLP-1 medication directly, and it often resolves with adequate protein intake and, where indicated, some extra targeted nutritional support. In short, it’s merely temporary in virtually all cases.

‍

• Muscle Loss - As we discussed way earlier, muscle loss is hands-down the most clinically significant and most preventable risk and side effect of GLP-1 therapy without appropriate support.

‍

While the aforementioned common side effects and risks are transient and manageable, here are some other side effects that are quite rare, but when they appear, they are very serious (these should be monitored through a detailed clinical review):

‍

• Acute pancreatitis
• Gallbladder disease (increased cholelithiasis risk paired with rapid weight loss)
• Non-arteritic anterior ischemic optic neuropathy

GLP-1 And Its Unique Role In The Context Of Dubai

‍

Dubai’s mixture of hot, tropical climate and a fast-moving, cosmopolitan population, among its other distinct elements as a global hub, does create some rather specific clinical considerations and challenges for GLP-1 therapy that are not well-covered in international clinical literature, or are well-recognised outside of the UAE:

1) Heat & Hydration

‍

The dangerous combination of both a GLP-1-induced appetite and thirst signalling, with ambient temperatures that rise above 40°C, can create a significant risk of dehydration, especially during those extremely hot summers. 

‍

As such, close electrolyte monitoring and active hydration guidance are non-negotiable components for patients seeking to undergo a GLP-1 therapy protocol in Dubai.

2) Ramadan

‍

Extended daily fasting during Ramadan also creates specific challenges for GLP-1 patients. These would include hurdles like a reduced eating window, which concentrates food intake even further, while the altered meal timing interacts negatively with gastric emptying dynamics, and then there’s the physiological stress of the Ramadan month itself that may affect your dose tolerability. 

‍

With that in mind, patients on GLP-1 therapy during Ramadan require specific protocol adjustments and an enhanced level of monitoring, just to be safe. Otherwise, we do not really advise that you begin initiating a GLP-1 therapy in the weeks immediately before Ramadan.

3) Frequent Long-Haul Travel

‍

This isn’t a huge surprise given Dubai’s place as a global transit hub for transatlantic and transpacific travel, and Dubai’s vast expat population do travel quite a lot, too.

‍

Nevertheless, disrupted meal timing from regular long-haul travel does affect both the GLP-1 patient’s caloric intake pattern and their gastrointestinal comfort. 

‍

Standard travel protocols, which would include strict dietary guidance for flights and adjustments to your meal timings, are normal parts of the onboarding conversation.

4) The Performance Community

‍

Of course, we’d be remiss to not mention the surprisingly significant proportion of Dubai’s population that will engage with GLP-1 therapy, which is also simultaneously training at a very high level.

‍

This would include HYROX, Lagree, triathlon, padel, and much more. So, for this group in particular, the muscle preservation imperative is further amplified, and losing lean mass while training competitively is not acceptable.

‍

On the contrary, it’s actually both a major health risk and it creates an unwanted setback to your performance. At Chairon House, for GLP-1 patients, our integrated training and monitoring approach is specifically designed for this unique patient profile.

‍

What does GLP-1 therapy cost in Dubai?

‍

The actual GLP-1 medication cost varies by agent and dose, but for reference, Mounjaro (tirzepatide) ranges from approximately AED 1,500 to AED 2,500 per month, depending on the dose. Meanwhile, Ozempic or Wegovy (semaglutide) ranges from approximately AED 1,200 to AED 2,000 per month. Naturally, these costs should be understood in the wider context of the full, complete protocol, which includes other expenses that you have to account for, such as consultation, monitoring, body composition assessment, and the integrated movement and nutritional components, too. The medication alone, without the rest of the clinical infrastructure, is not a complete treatment on its own.

Access GLP-1 Therapy At Chairon House

‍

If you’re interested in getting GLP-1 therapy, then look no further, as Chairon House is a DHA-licensed regenerative medicine and social wellness club located in Al Quoz, Dubai. Our extensive GLP-1 programme is not a prescription service, but rather, it is a detailed, comprehensive metabolic medicine protocol.

‍

And so, our integrated GLP-1 protocol includes the full complement, starting with the medication itself, movement and nutritional components, active monitoring, and the full adjunctive clinical support, and much more, all designed to produce body composition outcomes that are both meaningful and sustainable.

‍

We do not write prescriptions without a full clinical assessment, either, nor do we ever proceed with medication selection without a DEXA baseline and metabolic bloodwork. For us, safety is paramount, and we do not offer GLP-1 therapy without the integrated movement and nutritional components that determine whether the results will last.

Related Reading

‍

• [Ozempic vs Mounjaro vs Wegovy: Which GLP-1 Is Right for You? →]*
• [GLP-1 and Muscle Preservation: Why Your Protocol Needs More Than an Injection →]*
• [NAD+ for Metabolic Health & Weight Management UAE →]*
• [NAD+ IV Therapy Dubai: The Complete Guide →]*

‍

NOTE: This article is for informational purposes only, and it does not constitute medical advice. GLP-1 receptor agonists are prescription medications that must be prescribed and monitored by a DHA-licensed and trained physician. Always remember to consult a physician to determine whether this treatment is appropriate for your individual health profile.

‍